Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 19, 2026Clinical Cancer Research

Abstract PS3-09-25: Factors Associated With Real-World Use of Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early-Stage HR+/HER2- Breast Cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

PSP. SahaCSC. SanchezEvanston HospitalOIO. IsraelUniversity of Michigan

Discussion

Loading...

Member takes

Implication

Evaluates treatment choices and outcomes in premenopausal women with early-stage HR+/HER2- breast cancer, indicating possible underutilization of ovarian function suppression.

Key Points

  • The aim is to investigate factors affecting the choice between ovarian function suppression and tamoxifen in young women with breast cancer.
  • Analyzed medical records of premenopausal women with HR+/HER2- breast cancer from 2012 to 2023.
  • Collected demographic and treatment data, excluding women with non-invasive cancer or those not initiating therapy.
  • Conducted multivariable logistic regression to assess factors influencing treatment choice.
  • Of 723 eligible women, 185 received ovarian function suppression while 538 received tamoxifen alone.
  • Recurrence rates after a median follow-up of 66 months showed 13 in the OFS group versus 51 in the Tam group.
  • Early discontinuation due to toxicity was 14.5%, without significant differences between treatment groups.

Cite This Study

Saha et al. (2026) studied this question.

synapsesocial.com/papers/6996a85cecb39a600b3ef000https://doi.org/10.1158/1557-3265.sabcs25-ps3-09-25
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Trends in ovarian function suppression use among premenopausal women with breast cancer: A longitudinal analysis from 2015-2023.2026
  2. 2Abstract PS3-11-25: Adjuvant ovarian function suppression (OFS) in HR+/HER2+ premenopausal breast cancer (BC) patients with pathologic complete response (pCR) or residual disease (RD) after neoadjuvant chemotherapy (NAC): a real-world study2026
  3. 3Abstract PO1-01-12: A retrospective cohort study on the effect of adding adjuvant ovarian function suppression to endocrine therapy in premenopausal women with T1-T2 tumor hormone-positive breast cancer on survival and disease recurrence2024
  4. 4Ovarian Function Suppression in Premenopausal HR-positive, HER2-negative Early Breast Cancer: Integrating Clinical Trial Evidence and Findings from a Nationwide Korean Breast Cancer Society Survey2025
  5. 5Adjuvant Ovarian Function Suppression in Premenopausal Hormone Receptor–Positive Breast Cancer2024 · 3 citations